# DESCRIPTION

- introduce invention relating to binding molecules and therapeutic uses

## BACKGROUND OF THE INVENTION

- describe Alzheimer disease and its characteristics
- discuss Aβ peptides and their role in AD
- summarize research on N-truncated Aβ peptides
- describe transgenic mouse models of AD
- discuss the role of Aβ oligomers in AD
- highlight the need for new diagnostic and therapeutic tools

## SUMMARY OF THE INVENTION

- introduce antibody molecule capable of recognizing Aβ oligomers
- describe diagnostic tools for differentiating healthy controls from AD patients
- discuss N-terminal truncated Aβ starting with pyroglutamate (AβpE3)
- summarize generation of new diagnostic and pharmaceutically useful tools
- describe antibodies directed against oligomeric forms of Aβ
- highlight importance of antibodies in diagnosis of dementia and/or amyloid-related disorders
- introduce method of diagnosing a subject suspected of suffering from a disease associated with amyloidogenesis
- describe method of monitoring the efficacy of a treatment of a disease associated with amyloidogenesis
- introduce method of predicting the efficacy of a treatment of a disease associated with amyloidogenesis
- discuss therapeutic methods and substances reducing oligomeric AβpE3

## DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

- characterize antibodies in APP/PS1KI and 5xFAD mice
- analyze staining patterns in sporadic and familial AD cases
- observe intraneuronal staining in transgenic models
- detect strong immunostaining in human AD cases
- find negligible staining in healthy control specimens
- observe intraneuronal staining during aging
- recognize AβpE3-42 oligomers by antibodies
- do not cross-react with Aβ1-42
- use antibodies in diagnostic assays
- diagnose AD by comparing oligomer levels
- determine oligomer levels in biological samples
- compare with reference amounts
- diagnose disease when amounts differ
- monitor treatment efficacy
- predict treatment efficacy
- define binding molecules
- describe binding molecule properties
- exemplify binding molecules
- inhibit Aβ-oligomerization
- recognize soluble AβpE3 oligomers
- inhibit seeding effect of soluble AβpE3 oligomers
- use binding molecules in treatment and prevention of amyloid-related disorders
- define antibody
- describe antibody isotypes
- introduce antibody fragments
- describe monoclonal antibodies
- detail production of monoclonal antibodies
- specify deposited hybridomas
- describe CDRs and variable regions
- provide nucleic acid sequences
- describe identity of nucleic acid sequences
- introduce binding molecules with CDRs
- describe variants of variable regions
- provide antibodies with specific variable regions
- describe methods for preparing antibodies
- specify host cells for antibody production
- introduce hybridoma producing antibody molecule
- describe immunoblotting analysis
- describe immunoisolation methods
- describe immunostaining methods
- provide examples of immunoblotting
- provide examples of immunostaining
- describe ELISA test
- describe immunostaining with different biological samples
- characterize antibodies by immunohistochemistry
- describe staining with antibodies of the invention
- relate to a composition comprising a binding molecule
- describe a diagnostic composition
- describe a pharmaceutical composition
- describe the choice of carrier
- describe administration of the composition
- describe a method of treating or preventing an amyloid-related disorder
- describe preferred embodiments
- specify binding molecule properties
- define amyloid-related disorders
- describe antibody molecule properties
- outline pharmaceutical composition
- specify administration methods
- describe method of inhibiting oligomerization
- outline characteristics of binding substance
- describe method of treating or preventing amyloid-related disorder
- describe method of determining inhibition of oligomerization
- outline method for identifying agents useful in treatment and/or prevention of amyloid-related disorder
- define AβpE3
- describe thioflavin T aggregation assay
- determine rate of oligomerization and aggregation
- describe binding constant and inhibiting Aβ-oligomerization
- introduce antibody produced by hybridoma
- describe candidate agent
- provide examples of candidate agents
- describe nucleic acid molecules encoding antibody molecules
- describe vectors containing nucleic acid molecules
- provide examples of vectors
- describe host cell comprising nucleic acid molecule and/or vector
- describe transformation of host cell
- introduce antibody molecules for diagnosis
- describe diagnostic purposes
- list diseases associated with amyloidogenesis
- describe method of diagnosing disease
- specify biological samples
- describe method of diagnosing familial Alzheimer disease
- describe method of diagnosing sporadic Alzheimer disease
- describe in vitro samples
- describe in vivo methods
- describe method of monitoring treatment efficacy
- specify diseases associated with amyloidogenesis
- describe method of monitoring treatment efficacy for sporadic Alzheimer disease
- describe method of monitoring treatment efficacy for familial Alzheimer disease
- describe method of predicting treatment efficacy
- specify biological samples for predicting treatment efficacy
- describe method of predicting treatment efficacy for sporadic Alzheimer disease
- describe method of predicting treatment efficacy for familial Alzheimer disease
- define terms "subject" and "sample"
- define terms "reference" and "control samples"
- explain processing steps for samples
- describe validation of methodology
- describe kit composition

### EXAMPLES

- generate antibodies
- describe Western blot protocol
- perform statistical analysis
- describe immunohistochemistry on paraffin sections
- present dot blot results
- analyze Western blot results
- describe antibody 9D5H6 recognition
- differentiate between non-demented controls and Alzheimer disease patients
- present staining patterns in human brain samples
- introduce 5XFAD mice model
- describe antibody 9D5H6 staining in 5XFAD mice
- show age-dependent accumulation of AβpE3 in 5XFAD mice
- describe double-staining with 9D5H6 and GFAP/Iba-1
- introduce sandwich ELISA for plasma samples
- describe ELISA protocol
- present results of ELISA pilot study
- discuss significance of intraneuronal Aβ accumulation
- summarize previous research on intraneuronal Aβ
- describe inventors' previous work on AβpE3-42 toxicity
- introduce dot blot competition and ELISA competition
- describe dot blot competition protocol
- describe ELISA competition protocol
- present results of competition assays
- describe immunostaining competition
- describe epitope competition
- perform size-exclusion chromatography
- analyze binding properties
- conduct thioflavin T aggregation assay
- investigate antibody effects on aggregation
- administer antibodies to mouse model
- assess behavioral deficits
- measure anxiety levels
- discuss soluble oligomers in AD
- describe therapeutic potential of 9D5
- evaluate diagnostic properties of 9D5
- perform passive immunization with antibodies
- analyze extracellular Aβ load
- present plaque-load quantification results
- hypothesize therapeutic mechanism
- describe 9D5 passive immunization method
- present Aβ40 and Aβ42 plaque load reduction results
- introduce non-human primate models for Alzheimer's disease
- describe tissue preparation and staining methods
- present AD-like pathology results in non-human primates
- rule out cross-reactivity with other organs
- present microglia cell visualization results
- describe passive immunization with 2-48 antibody method
- present plaque load reduction results with 2-48 antibody
- discuss implications of results

